GLP-1 Weight Loss Drugs Linked to Ear and Eustachian Tube Problems

GLP-1 receptor agonists may cause eustachian tube dysfunction due to tissue shrinkage from rapid weight loss, leading to ear fullness and hearing changes.

Pak, Kaitlynne Y et al.·Otology & neurotology : official publication of the American Otological Society·2025·Preliminary EvidenceCase Report
RPEP-12920Case ReportPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Case Report
Evidence
Preliminary Evidence
Sample
N=2
Participants
2 case patients with patulous ETD on GLP-1 drugs. FDA FAERS database: 97,237 GLP-1 adverse events reviewed. Systematic review of 937 articles.

What This Study Found

GLP-1 receptor agonists were associated with eustachian tube dysfunction, particularly the patulous variant, likely caused by rapid loss of soft tissue bulk around the eustachian tube opening.

Key Numbers

  • 97,237 total GLP-1 adverse events in FAERS
  • 958 (0.99%) were ear-related
  • Exenatide: highest proportion of ear AEs (1.52%)
  • Semaglutide: 1.17% ear AEs
  • Liraglutide: 1.16% ear AEs
  • Dulaglutide: 417 total ear AEs (highest count)
  • Systematic review: 937 articles screened, 10 met criteria

How They Did This

Combined case report, FDA Adverse Event Reporting System (FAERS) database analysis, and PRISMA-guided systematic literature review examining otolaryngologic adverse events of GLP-1 RAs.

Why This Research Matters

As GLP-1 drugs become widely used for weight loss, clinicians need to recognize ear symptoms as a potential side effect. Eustachian tube dysfunction can significantly impact quality of life, and early recognition may lead to better management.

The Bigger Picture

This is an emerging side effect that parallels other rapid-weight-loss complications. As the GLP-1 drug market expands, understanding the full spectrum of adverse effects beyond GI symptoms becomes critical for comprehensive patient care.

What This Study Doesn't Tell Us

Case reports and database analysis cannot establish causation; FAERS data is subject to reporting bias; small number of documented cases; unclear incidence rate in the broader GLP-1 RA population.

Questions This Raises

  • ?Is eustachian tube dysfunction reversible if GLP-1 therapy is paused or the rate of weight loss slows?
  • ?Are certain GLP-1 drugs or dosing regimens more likely to cause this side effect?
  • ?Could prophylactic ENT monitoring be warranted for patients on long-term GLP-1 therapy?

Trust & Context

Key Stat:
FAERS database + case series Analysis linking GLP-1 receptor agonists to eustachian tube dysfunction from tissue volume loss
Evidence Grade:
Case reports and database review — lowest level of clinical evidence but important for identifying novel adverse events. Signals warrant further investigation.
Study Age:
Published in 2025, capturing an emerging adverse effect of the rapidly expanding GLP-1 drug class.
Original Title:
GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
Published In:
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 46(1), 19-22 (2025)
Database ID:
RPEP-12920

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Describes what happened to one person or a small group.

What do these levels mean? →

Frequently Asked Questions

What is eustachian tube dysfunction?

The eustachian tube connects your middle ear to the back of your throat and helps equalize ear pressure. When it doesn't work properly, you can experience ear fullness, muffled hearing, or hear your own voice too loudly (autophony).

Why would a weight loss drug affect your ears?

GLP-1 drugs cause rapid loss of body fat, including the soft tissue around the eustachian tube opening in the throat. When this tissue shrinks, the tube can stay abnormally open, causing uncomfortable ear symptoms.

Read More on RethinkPeptides

Cite This Study

RPEP-12920·https://rethinkpeptides.com/research/RPEP-12920

APA

Pak, Kaitlynne Y; Cutri, Raffaello M; Nadeem, Wasiq; Kothari, Dhruv; Wong, Yu-Tung; Wu, Arthur W; Miller, Mia E. (2025). GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 46(1), 19-22. https://doi.org/10.1097/MAO.0000000000004373

MLA

Pak, Kaitlynne Y, et al. "GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.." Otology & neurotology : official publication of the American Otological Society, 2025. https://doi.org/10.1097/MAO.0000000000004373

RethinkPeptides

RethinkPeptides Research Database. "GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: ..." RPEP-12920. Retrieved from https://rethinkpeptides.com/research/pak-2025-glp1-receptor-agonist-induced

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.